Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
National Clinical Research Center for Hematologic Disease, Beijing, China.
Blood Adv. 2021 Dec 14;5(23):4910-4921. doi: 10.1182/bloodadvances.2021004349.
Intracranial hemorrhage (ICH) is a rare but fatal central nervous system complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, factors that are predictive of early mortality in patients who develop ICH after undergoing allo-HSCT have not been systemically investigated. From January 2008 to June 2020, a total of 70 allo-HSCT patients with an ICH diagnosis formed the derivation cohort. Forty-one allo-HSCT patients with an ICH diagnosis were collected from 12 other medical centers during the same period, and they comprised the external validation cohort. These 2 cohorts were used to develop and validate a grading scale that enables the prediction of 30-day mortality from ICH in all-HSCT patients. Four predictors (lactate dehydrogenase level, albumin level, white blood cell count, and disease status) were retained in the multivariable logistic regression model, and a simplified grading scale (termed the LAWS score) was developed. The LAWS score was adequately calibrated (Hosmer-Lemeshow test, P > .05) in both cohorts. It had good discrimination power in both the derivation cohort (C-statistic, 0.859; 95% confidence interval, 0.776-0.945) and the external validation cohort (C-statistic, 0.795; 95% confidence interval, 0.645-0.945). The LAWS score is the first scoring system capable of predicting 30-day mortality from ICH in allo-HSCT patients. It showed good performance in identifying allo-HSCT patients at increased risk of early mortality after ICH diagnosis. We anticipate that it would help risk stratify allo-HSCT patients with ICH and facilitate future studies on developing individualized and novel interventions for patients within different LAWS risk groups.
颅内出血 (ICH) 是异基因造血干细胞移植 (allo-HSCT) 后罕见但致命的中枢神经系统并发症。然而,对于 allo-HSCT 后发生 ICH 的患者,哪些因素可预测其早期死亡率尚未得到系统研究。2008 年 1 月至 2020 年 6 月,共纳入 70 例 allo-HSCT 患者,这些患者均被诊断为 ICH,形成了推导队列。同期,从其他 12 个医疗中心共收集了 41 例 allo-HSCT 患者,这些患者被诊断为 ICH,构成外部验证队列。本研究使用这 2 个队列开发并验证了一个分级量表,该量表可预测 allo-HSCT 患者 ICH 后的 30 天死亡率。多变量逻辑回归模型保留了 4 个预测因素(乳酸脱氢酶水平、白蛋白水平、白细胞计数和疾病状态),并建立了简化分级量表(称为 LAWS 评分)。该评分在推导队列(Hosmer-Lemeshow 检验,P >.05)和外部验证队列(Hosmer-Lemeshow 检验,P >.05)中均具有良好的校准度。在推导队列(C 统计量为 0.859,95%置信区间为 0.776-0.945)和外部验证队列(C 统计量为 0.795,95%置信区间为 0.645-0.945)中,该评分均具有良好的区分能力。LAWS 评分是第一个能够预测 allo-HSCT 患者 ICH 后 30 天死亡率的评分系统。它在确定 allo-HSCT 患者在 ICH 诊断后早期死亡风险增加方面表现良好。我们预计,它将有助于对 allo-HSCT 患者进行风险分层,并为不同 LAWS 风险组患者制定个性化和新型干预措施的未来研究提供帮助。